| Therapeutic | Basiliximab |
| Target | IL2RA |
| Heavy Chain | QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS |
| Light Chain | QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK |
| 100% seqID Fv Structure | 1mim [Fvs: HL], 3iu3 [Fvs: AB, CD, HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 1mim [Fvs: HL] |
| 100% seqID Structure | 3iu3 [Fvs: AB, CD, HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | NFD |
| Recorded Developmental Technology | na |
| INN Year Proposed | 1996 |
| INN Year Recommended | 1997 |
| Companies Involved | Cerimon Pharmaceuticals, Novartis |
| Conditions Approved | Renal transplant rejection, Transplant rejection |
| Conditions Active | na |
| Conditions Discontinued | Ulcerative colitis, Uveitis |
| Notes |
